Clincosm LogoSign in Get a demo

Integrin β7, BCMA, CS1, CD38 and CD138 as the Single or Compound Targets for the Fourth Genenation of CAR-T Cells

Sponsor
The Sixth Affiliated Hospital of Wenzhou Medical University (Other)
Overall Status
Recruiting
CT.gov ID
NCT03778346
Collaborator
Zhejiang Qixin Biotech (Other)
30
Enrollment
3
Locations
1
Arm
49.5
Anticipated Duration (Months)
10
Patients Per Site
0.2
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

According to the high expression of tumor cell-associated antigen CD138, integrin β7, CS1, CD38 and BCMA in patients with refractory/recurrent multiple myeloma, the fourth generation of CAR-T cells(simultaneously expressing IL7 and CCL19) with 10 different dual target combinations are used to minimize the tumor burden in the patient individually and precisely and improve the immunosuppressive microenvironment of the tumor , thereby effectively treating refractory/recurrent multiple myeloma .

Condition or Disease Intervention/Treatment Phase
  • Biological: CAR-T therapy in Relapsed/Refractory multiple myeloma
 Phase 1

Detailed Description

Multiple myeloma（MM） is one of the most common malignant diseases in the blood system.There is still no cure for the disease which only control the development of the disease in various ways including proteasome inhibitors and immune regulator and hematopoietic stem cell transplantation . Combined with the advantages of multiple therapies, chimeric antigen receptor T cells (CAR-T) have gradually becoming one of the strongest and most powerful weapons against multiple myeloma.The basic principle is to use the patient's own immune cells to clear cancer cells.

MM is genetically and phenotypically heterogeneous,Antigen escape and relapse after CAR-T treatment is a global problem， so the effective treatment of refractory/relapsing multiple myeloma with CAR-T cells usually requires targeting multiple antigens. The investigators use Integrin β7(a large family of molecules that are central regulators in multicellular biology and orchestrating cell-cell and cell-extracellular matrix (ECM) adhesive interactions from embryonic development to mature tissue function), BCMA(highly expressed on malignant MM plasma cells and providing a substantial antiapoptotic signal making it an encouraging target for BCMA-directed immunotherapy),CS1(encoded by the SLAMF7 gene,a robust marker of normal plasma cells and malignant plasma),CD38(encoded by the CD38 gene and functioning in cell adhesion, signal transduction and calcium signaling) and CD138(known as syndecan 1, a surface protein expressed on most healthy and malignant plasma cells as an adhesion protein, binding collagen and fibronectin molecules located in the extracellular matrix. ) as the Single or Compound Targets for the Fourth Genenation of CAR-T Cells ,thereby effectively treating refractory/recurrent multiple myeloma .

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Integrin β7, BCMA, CS1, CD38 and CD138 as the Single or Compound Targets for the Fourth Genenation of CAR-T Cells
Actual Study Start Date :
Nov 15, 2018
Anticipated Primary Completion Date :
Jun 30, 2022
Anticipated Study Completion Date :
Dec 31, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: CAR-T therapy in multiple myeloma

In order to assess the safety and validity of using the Fourth Genenation of CAR-T therapy refractory/rela-psed multiple myeloma patients with one kind of BCMA-CART,CD138-CART,CD38-CART , Integrin β7-CART or 10 different combinations ,subjects will receive 10^6-10^7/Kg transduced CAR-T cells at one time.

Biological: CAR-T therapy in Relapsed/Refractory multiple myeloma
Integrin β7, BCMA, CS1, CD38 and CD138 as the Single or Compound Targets for the Fourth Genenation of CAR-T Cells to treat Relapsed/Refractory multiple myeloma

Outcome Measures

Primary Outcome Measures

  1. Adverse events that are related to treatment [2 years]

    Safety and tolerability measured by occurrence of study related adverse effects defined by NCI-CTCAE v4.03

Secondary Outcome Measures

  1. 2 year overall survival(OS) [2 yaers]

    To estimate 2 year overall survival(OS) after BCMA/CD138/CD38/Integrinβ7/CS1-CART infusion and sequential treatment with Relapsed/Refractory MM

  2. 3 year progression free survival (PFS) [3 yaers]

    To estimate 3 year progression free survival after BCMA/CD138/CD38/Integrinβ7/CS1 CART infusion and sequential treatment with Relapsed/Refractory MM

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

  1. Patients who meet the requirements voluntarily participate in the study and sign the Informed Consent Form.

  2. Age is 18 to 80 years old, gender is not limited.

  3. Patients with relapsed or refractory myeloma who meet the following criteria for multiple myeloma diagnostic criteria defined by the IMWG (2017): Subjects have received adequate prior treatment of at least 2 regimens; during the most recent treatment or after treatment , the disease progresses or recurs.

  4. The Eastern Cancer Cooperative Group (ECOG) scores 0 to 2 (the tumor causes bone pain).

  5. The expected survival period is more than 12 weeks.

  6. No other malignant tumors, severe autoimmune diseases or congenital immunodeficiency, serious progressive infection, cranial nerve disorder or mental illness.

Exclusion Criteria:

  1. Pregnant or lactating women.

  2. Patients with uncontrollable active infections.

  3. Patients with systemic steroids; recent or current use of inhaled steroids is not excluded.

  4. Previously involved CAR-T cell therapies produced any uncontrolled disease.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Jinhong Jiang Lishui Zhejiang China 323000
2 The Sixth Affiliated Hospital of Wenzhou Medical University Lishui Zhejiang China 323000
3 Zhejiang QiXin Biotech Wenzhou Zhejiang China 325035

Sponsors and Collaborators

  • The Sixth Affiliated Hospital of Wenzhou Medical University
  • Zhejiang Qixin Biotech

Investigators

  • Principal Investigator: Bingmu Fang, M.D, Lishui Country People's Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
The Sixth Affiliated Hospital of Wenzhou Medical University
ClinicalTrials.gov Identifier:
NCT03778346
Other Study ID Numbers:
  • SixthAHWenzhouMU
First Posted:
Dec 19, 2018
Last Update Posted:
Nov 18, 2020
Last Verified:
Nov 1, 2020
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Nov 18, 2020